First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Baird R, Fischer S, Azaro A, Harstrick A, Stumpp M, Leupin N, Dawson K, Fiedler U, Zitt C, Rodón J, Harris A, Lord S, Middleton M, Linossi C, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. J Clin Oncol 2020; 39:145-154.
10.12.2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
10.12.2020
J Clin Oncol 2020; 39:145-154
Baird Richard D, Fischer Stefanie, Azaro Analia, Harstrick Andreas, Stumpp Michael T, Leupin Nicolas, Dawson Keith M, Fiedler Ulrike, Zitt Christof, Rodón Jordi, Harris Adrian, Lord Simon, Middleton Mark, Linossi Constanza, Omlin Aurelius
Weiter
